CD19 and non-Hodgkin lymphoma: As for the impact on macrophage function, targeting CD47 augmented the phagocytic efficiency of macrophages on CFSE-labeled NHL cells in antibodies present groups when opposed to CD19-CAR T cell monotherapy group (Fig. 7F-G).